바이젠셀

308080KOSDAQ

63.8 / 100

Reference Date: 2026-09-08

Financial Score17.5 / 40

News Sentiment21.3 / 25

Momentum15.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 23.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Bizen Cell is a biotech venture company established in 2013, specializing in the development and manufacturing of immunotherapy drugs. Leveraging its HLA research expertise and utilizing umbilical cord blood-derived immune therapies, the company is advancing as a cell therapy specialist through pipelines such as ViTier and ViMedier, while expanding into global new drug development and advanced regenerative medicine.

Number of Employees

43people

Average Salary

86.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

—Industry Average 1.203.5Point

ROE

-32.09Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

20.24Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼91.9% (1-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲6.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -25.3% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
국내 첫 ‘첨단재생의료 치료’ 시작
바이젠셀의 첨단 재생의료 치료제 VT-EBV-N이 국내 최초로 희귀림프종 환자 치료에 적용되어 긍정적인 시장 반응을 이끌어냈다.
Positive
국내 첨단재생의료 치료 1호 개시…바이젠셀 치료제 활용
바이젠셀의 첨단재생의료 치료제 'VT-EBV-N'이 국내 최초로 승인되어 희귀 림프종 환자 치료에 본격적으로 활용되기 시작함.

Detailed Momentum

52-week position3.0Point

52w lower range (27%)

Current 6,640Won52-week high 15,80052-week low 3,090

1-month return6.0Point

1m +22.96% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14